183 related articles for article (PubMed ID: 19602071)
1. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
Turza K; Dengel LT; Harris RC; Patterson JW; White K; Grosh WW; Slingluff CL
J Cutan Pathol; 2010 Jan; 37(1):94-8. PubMed ID: 19602071
[TBL] [Abstract][Full Text] [Related]
2. [Topical treatment of melanoma skin metastases with imiquimod].
Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M
Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347
[TBL] [Abstract][Full Text] [Related]
3. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
Heber G; Helbig D; Pönitzsch I; Wetzig T; Harth W; Simon JC
J Dtsch Dermatol Ges; 2009 Jun; 7(6):534-6. PubMed ID: 19250248
[TBL] [Abstract][Full Text] [Related]
4. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
[TBL] [Abstract][Full Text] [Related]
5. Topical treatment of melanoma skin metastases with imiquimod: a review.
Sisti A; Sisti G; Oranges CM
Dermatol Online J; 2015 Feb; 21(2):. PubMed ID: 25756475
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
7. Use of imiquimod for residual acral melanoma.
Sue GR; Hanlon A; Lazova R; Narayan D
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25188932
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod clears invasive melanoma.
Grady BE; Spencer JM
Cutis; 2016 Nov; 98(5):E28-E30. PubMed ID: 28040822
[TBL] [Abstract][Full Text] [Related]
9. [Imiquimod for the treatment of skin metastases of melanoma].
Nagore E; Botella-Estrada R; Sanmartín O; Guillén C
Actas Dermosifiliogr; 2005 Oct; 96(8):549-50. PubMed ID: 16476296
[No Abstract] [Full Text] [Related]
10. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
11. Progress of multiple cutaneous and subcutaneous melanoma metastases of the face during imiquimod treatment.
Kowalzick L; Eickenscheidt L
J Dtsch Dermatol Ges; 2009 Jun; 7(6):538-40. PubMed ID: 19298548
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Muñoz CM; Sánchez JL; Martín-García RF
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
[TBL] [Abstract][Full Text] [Related]
13. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Read T; Webber S; Thomas J; Wagels M; Schaider H; Soyer HP; Smithers BM
BMJ Open; 2017 Oct; 7(10):e016816. PubMed ID: 28988173
[TBL] [Abstract][Full Text] [Related]
14. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Florin V; Desmedt E; Vercambre-Darras S; Mortier L
Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Park AJ; Paul J; Chapman MS; Samie FH
Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod as an antiaging agent.
Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R
J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874
[TBL] [Abstract][Full Text] [Related]
18. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
19. Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
Rivas-Tolosa N; Ortiz-Brugués A; Toledo-Pastrana T; Baradad M; Traves V; Soriano V; Sanmartín V; Requena C; Martí R; Nagore E
J Dermatol; 2016 May; 43(5):553-6. PubMed ID: 26660713
[TBL] [Abstract][Full Text] [Related]
20. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.
Ugurel S; Wagner A; Pföhler C; Tilgen W; Reinhold U
Br J Dermatol; 2002 Sep; 147(3):621-4. PubMed ID: 12207622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
